PHASE II RHIL-12 IN MF WITH CROSS-OVER TO PHASE I IL-2 ADMINISTERED WITH IL-12

MF 中的 II 期 RHIL-12 与 IL-12 联合给药的 I 期 IL-2 交叉

• 批准号: 7375495
• 负责人: GARY S WOOD
• 金额: $ 0.03万
• 依托单位: UNIVERSITY OF WISCONSIN-MADISON
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7375495
• 关键词: PHASE; II; RHIL; 12; MF

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study is closed to new enrollment at this site. This clinical trial is testing a new therapy for a type of cancer known as cutaneous T-cell lymphoma. The treatment involves injections of two types of small proteins known as cytokines: interleukin-12 and interleukin-2.

该子项目是利用 NIH/NCRR 资助的中心拨款提供的资源的众多研究子项目之一。子项目和研究者 (PI) 可能已从另一个 NIH 来源获得主要资金，因此可以在其他 CRISP 条目中出现。列出的机构是中心的机构，不一定是研究者的机构。该研究已停止接受本网站的新注册。 这项临床试验正在测试一种针对皮肤 T 细胞淋巴瘤的癌症的新疗法。该治疗涉及注射两种称为细胞因子的小蛋白质：白细胞介素 12 和白细胞介素 2。